[Anasarca, a complication of chemotherapy with gemcitabine in two patients with pancreatic cancer]

Gastroenterol Clin Biol. 2007 Dec;31(12):1143-5. doi: 10.1016/s0399-8320(07)78353-7.
[Article in French]

Abstract

Pancreatic adenocarcinoma is the fifth most common cause of cancer-related mortality in the world. The nucleoside analogue gemcitabine is the established standard therapy for advanced disease. Rare cases of gemcitabine-associated systemic capillary leak syndrome have been reported. Here, we present two cases of capillary-leak syndrome in patients with pancreatic cancer treated with gemcitabine.

Publication types

  • Case Reports
  • English Abstract

MeSH terms

  • Adenocarcinoma / drug therapy*
  • Adenocarcinoma / secondary
  • Aged
  • Antimetabolites, Antineoplastic / adverse effects*
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Capillary Leak Syndrome / chemically induced*
  • Deoxycytidine / adverse effects
  • Deoxycytidine / analogs & derivatives*
  • Edema / chemically induced*
  • Fatal Outcome
  • Female
  • Gemcitabine
  • Humans
  • Liver Neoplasms / secondary
  • Male
  • Middle Aged
  • Neoadjuvant Therapy
  • Pancreatic Neoplasms / drug therapy*
  • Peritoneal Neoplasms / secondary
  • Radiotherapy, Adjuvant
  • Ribonucleotide Reductases / antagonists & inhibitors*

Substances

  • Antimetabolites, Antineoplastic
  • Deoxycytidine
  • Ribonucleotide Reductases
  • Gemcitabine